AstraZeneca announced today announced a deal with Immunocore for access to the latter's Tcell immuno platform for targeting cancer antigens -- the so-called ImmTac technology. The technology will be used by AZ's MedImmune bio unit to develop cancer therapies. The deal calls for an upfront payment of $20 M and if structured similarly to deals announced last year with GSK and Genentech, would also earn up to $300 M in milestone payments. AZ continues to add assets to its oncology portfolio and is gearing up to make a bigger splash on the biologics side of the market as its core small molecule drugs continue to hit their patent expirations in the very near term with no ready replacments on the short term horizon. This deal might also be one that could fuel products that could go into the Celltrion facility if AZ's attempt at a buy-out there is successful. See BioPharma-Reporter.com.
Posted by Bruce Lehr Jan 8th 2014.